Weiss A T, Fine D G, Applebaum D, Welber S, Sapoznikov D, Lotan C, Mosseri M, Hasin Y, Gotsman M S
Chest. 1987 Jul;92(1):124-8. doi: 10.1378/chest.92.1.124.
Thirty-four patients with acute myocardial infarction were treated prospectively using a new strategy of prehospital intravenous streptokinase given by a physician-operated mobile intensive care unit. The 29 prehospital-treated patients who had experienced no previous myocardial infarction were compared to a similar group treated with streptokinase inhospital. Patients receiving streptokinase in the prehospital phase of acute myocardial infarction had smaller infarcts and better residual myocardial function than the group given streptokinase inhospital in terms of peak creatinine phosphokinase, ejection fraction, computer-derived dysfunction index, and electrocardiographic QRS score. The only difference between these groups at baseline was the duration of pain prior to initiation of streptokinase therapy. There were no major complications related to prehospital administration of streptokinase.
34例急性心肌梗死患者采用一种新策略进行前瞻性治疗,即由医生操作的移动重症监护单元在院前静脉给予链激酶。将29例既往无心肌梗死病史且接受院前治疗的患者与一组在医院接受链激酶治疗的类似患者进行比较。就峰值肌酸磷酸激酶、射血分数、计算机衍生功能障碍指数和心电图QRS评分而言,急性心肌梗死院前阶段接受链激酶治疗的患者梗死面积较小,残余心肌功能较好。这些组在基线时的唯一差异是链激酶治疗开始前的疼痛持续时间。院前给予链激酶未出现重大并发症。